{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:25:43Z","timestamp":1794306343616,"version":"4.9.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenstr\u00f6m macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients with WM. This ad hoc analysis examined treatment outcomes with zanubrutinib or ibrutinib on PN symptoms associated with WM in patients enrolled in ASPEN. Logistic regression was performed between PN symptom resolution and several predictors. Health-related quality of life (HRQOL) was assessed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. Forty-nine patients with PN symptoms were included (zanubrutinib treated, n\u00a0=\u00a027; ibrutinib treated, n\u00a0=\u00a022). Overall, 35 patients (71.4%) experienced resolution of PN symptoms, with a median time to resolution of 10.1\u00a0months (range, 1-46.8). In cohort 1 (MYD88 mutation), the median time to PN symptom resolution was 4.6\u00a0months (range, 1.1-46.8) with zanubrutinib and 14.1\u00a0months (range, 1-44) with ibrutinib. Logistic regression demonstrated a significant relationship between PN symptom resolution and both major response and lower baseline anti\u2013myelin-associated glycoprotein antibody levels. Patients with PN symptom resolution had greater improvement in HRQOL. Physical functioning improved in patients with PN symptom resolution and was unchanged in patients without resolution. Improvements observed in PN symptoms may be in response to a reduction in immunoglobulin M. Although further investigation is required, this analysis supports the potential use and further exploration of Bruton tyrosine kinase inhibitors to treat PN symptoms in patients with WM. This trial was registered at www.clinicaltrials.gov as #NCT03053440.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014115","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T17:28:39Z","timestamp":1733246919000},"page":"722-728","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1182","volume":"9","author":[{"given":"Benjamin M.","family":"Heyman","sequence":"first","affiliation":[{"name":"1Hematology, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen S.","family":"Opat","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Karolinska Universitetssjukhuset Solna, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios C.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"4Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"5Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"6ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"7Alfred Hospital, Melbourne, VIC, Australia"},{"name":"8Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[{"name":"9Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm, University Hospital Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Owen","sequence":"additional","affiliation":[{"name":"10St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[{"name":"11Sorbonne University, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"12Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisoo","family":"Barnes","sequence":"additional","affiliation":[{"name":"13BeiGene USA, Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"13BeiGene USA, Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Schneider","sequence":"additional","affiliation":[{"name":"13BeiGene USA, Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Allewelt","sequence":"additional","affiliation":[{"name":"13BeiGene USA, Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Cohen","sequence":"additional","affiliation":[{"name":"13BeiGene USA, Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[{"name":"14Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"11","key":"2025032418271977200_bib1","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41375-019-0592-8","article-title":"What is new in the treatment of Waldenstrom macroglobulinemia?","volume":"33","author":"Castillo","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"2025032418271977200_bib2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2025032418271977200_bib3","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood.V118.21.3692.3692","article-title":"Incidence of peripheral neuropathy in Waldenstr\u00f6m macroglobulinemia patients at diagnosis","volume":"118","author":"Paba-Prada","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2025032418271977200_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S0317167100011483","article-title":"The neuropathies of Waldenstrom's macroglobulinemia (WM) and IgM-MGUS","volume":"38","author":"Klein","year":"2011","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"2025032418271977200_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp.2005.071175","article-title":"Peripheral neuropathies in Waldenstrom's macroglobulinaemia","volume":"77","author":"Levine","year":"2006","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025032418271977200_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1529-8027.2012.00376.x","article-title":"Heterogeneous spectrum of neuropathies in Waldenstrom's macroglobulinemia: a diagnostic strategy to optimize their management","volume":"17","author":"Viala","year":"2012","journal-title":"J\u00a0Peripher Nerv Syst"},{"issue":"suppl 1","key":"2025032418271977200_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136558","article-title":"Neuropathy with IgM gammopathy: incidence, characteristics and management, a Rory Morrison W.M.U.K Registry analysis","volume":"136","author":"Tomkins","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025032418271977200_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nic.2013.03.023","article-title":"Peripheral neuropathy: clinical and electrophysiological considerations","volume":"24","author":"Chung","year":"2014","journal-title":"Neuroimaging Clin N Am"},{"issue":"7","key":"2025032418271977200_bib9","first-page":"383","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"Yeung","year":"1991","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"2025032418271977200_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/01913129709016367","article-title":"Myelin modifications in 8 cases of peripheral neuropathy with Waldenstrom's macroglobulinemia and anti-MAG activity","volume":"21","author":"Vital","year":"1997","journal-title":"Ultrastruct Pathol"},{"issue":"5","key":"2025032418271977200_bib11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal gammopathy\u2013associated peripheral neuropathy: diagnosis and management","volume":"92","author":"Chaudhry","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"1-2","key":"2025032418271977200_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2014.01.012","article-title":"Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy","volume":"268","author":"Stork","year":"2014","journal-title":"J\u00a0Neuroimmunol"},{"issue":"10","key":"2025032418271977200_bib13","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2025032418271977200_bib14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"issue":"25","key":"2025032418271977200_bib15","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025032418271977200_bib16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstr\u00f6m associated peripheral neuropathies: recommendations from the IWW-8 consensus panel","volume":"176","author":"D'Sa","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"2025032418271977200_bib17","first-page":"1975","article-title":"Ibrutinib and rituximab in Waldenstrom's macroglobulinemia","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2025032418271977200_bib18","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A\u00a0randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"33","key":"2025032418271977200_bib19","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025032418271977200_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2025032418271977200_bib21","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","article-title":"Treatment recommendations for patients with Waldenstr\u00f6m macroglobulinemia (WM) and related disorders: IWWM-7 consensus","volume":"124","author":"Dimopoulos","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2025032418271977200_bib22","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2025032418271977200_bib23","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025032418271977200_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025032418271977200_bib25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp-2017-316689","article-title":"High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy","volume":"89","author":"Vos","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2025032418271977200_bib26","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.3324\/haematol.2017.177444","article-title":"IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies","volume":"103","author":"Allain","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 15","key":"2025032418271977200_bib27","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1200\/jco.2010.28.15_suppl.8114","article-title":"Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM)","volume":"28","author":"Treon","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2025032418271977200_bib28","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032418271977200_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eurger.2015.02.006","article-title":"Causes of neuropathy in the elderly: a retrospective study with 785 patients","volume":"6","author":"Mathis","year":"2015","journal-title":"Eur Geriatr Med"},{"issue":"suppl 1","key":"2025032418271977200_bib30","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1182\/blood-2018-99-111444","article-title":"Health-related quality of life in Waldenstrom macroglobulinemia (WM) and IgM monoclonal gammopathy of undeterminated significance (IgM-MGUS)","volume":"132","author":"Frustaci","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025032418271977200_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jha2.640","article-title":"Patient reported outcome measures in Waldenstrom macroglobulinaemia: a real-world data analysis from the WMUK Rory Morrison Registry","volume":"4","author":"Khwaja","year":"2023","journal-title":"EJHaem"},{"issue":"4","key":"2025032418271977200_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology"},{"issue":"23","key":"2025032418271977200_bib33","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","article-title":"Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness","volume":"83","author":"Draak","year":"2014","journal-title":"Neurology"},{"issue":"suppl 1","key":"2025032418271977200_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2023-185113","article-title":"Prospective study of acalabrutinib with rituximab in patients with symptomatic anti-MAG mediated IgM peripheral neuropathy","volume":"142","author":"Sarosiek","year":"2023","journal-title":"Blood"},{"issue":"suppl 2","key":"2025032418271977200_bib35","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S2152-2650(21)02168-6","article-title":"P-034: MAGNAZ trial - A prospective phase II study in patients with monoclonal gammopathy of unknown significance (MGUS) and anti-myelin associated glycoprotein (MAG) neuropathy and zanubrutinib treatment","volume":"21","author":"Minnema","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/722\/2355641\/blooda_adv-2024-014115-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/722\/2355641\/blooda_adv-2024-014115-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T16:06:09Z","timestamp":1742832369000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/722\/534296\/Peripheral-neuropathy-in-the-phase-3-ASPEN-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014115","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}